Share on StockTwits

Integra LifeSciences Holdings Corp. (NASDAQ:IART) Director Stuart Essig unloaded 21,381 shares of Integra LifeSciences Holdings Corp. stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.76, for a total value of $1,021,156.56. Following the transaction, the director now directly owns 1,035,428 shares in the company, valued at approximately $49,452,041. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.19% during mid-day trading on Tuesday, hitting $47.20. The stock had a trading volume of 98,984 shares. Integra LifeSciences Holdings Corp. has a 1-year low of $35.73 and a 1-year high of $49.99. The stock’s 50-day moving average is $45.63 and its 200-day moving average is $46.40. The company’s market cap is $1.537 billion.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.57 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.58 by $0.01. The company had revenue of $215.00 million for the quarter, compared to the consensus estimate of $213.30 million. During the same quarter in the prior year, the company posted $0.39 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts predict that Integra LifeSciences Holdings Corp. will post $2.94 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Oppenheimer cut their price target on shares of Integra LifeSciences Holdings Corp. from $57.00 to $55.00 in a research note on Friday, May 2nd. They now have an “outperform” rating on the stock. Analysts at Lake Street Capital initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, April 23rd. They set a “buy” rating and a $55.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $51.86.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.